{"preliminary_commentary":{"by_channel":{"x_thread":2,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":"resectable stage II–IIIB EGFR-mutant lung adenocarcinoma","name":"NeoIpower","nct_id":"NCT05104788","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=neoipower-nct05104788. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"NeoIpower","arms":[{"description":"Icotinib 125 mg TID plus investigator's choice of platinum-based standard of care chemotherapy (pemetrexed/carboplatin or pemetrexed/cisplatin)","label":"Icotinib with platinum-based chemotherapy","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2026-12-01","type":"ESTIMATED"},"conditions":["Non-Small Cell Lung Cancer"],"enrollment":{"count":27,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Icotinib","otherNames":[],"type":"DRUG"},{"name":"Cisplatin","otherNames":[],"type":"DRUG"},{"name":"Carboplatin","otherNames":[],"type":"DRUG"},{"name":"Pemetrexed","otherNames":[],"type":"DRUG"}],"last_update":"2021-11-03","lead_sponsor":"Peking University Cancer Hospital & Institute","official_title":"A Phase II, Single-Arm, Prospective Study of Neoadjuvant Icotinib With Chemotherapy for the Treatment of Patients With Epidermal Growth Factor Receptor Mutation Positive, Resectable for Stage II to IIIB(N2) Non-small Cell Lung Cancer","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2024-03-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Major Pathological Response (MPR)","timeFrame":"From date of randomization to an average of 12 weeks after the first dose"}],"references":[],"start_date":{"date":"2021-10-25","type":"ESTIMATED"},"study_type":"INTERVENTIONAL","title":"A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer","url":"https://clinicaltrials.gov/study/NCT05104788"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/neoipower-nct05104788"}